Drugs / Ampicillin-sulbactam
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT05922124 | Sep 2024 → Jul 2026 overdue | Acinetobacter infectious disease | Rambam Health Care Campus | Recruiting | No outcome recorded |
| Phase 4 | NCT06448624 | Apr 2024 → Jan 2025 | congenital heart block, prosthesis-related infectious disease | Universitas Diponegoro | Completed | No outcome recorded |
| Phase 4 | NCT01138852 | Jul 2004 → Dec 2008 | — | Attikon Hospital | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT06336213 | Jan 2024 → Dec 2026 expected | heart valve disorder, thoracic aortic aneurysm | Petrovsky National Research Centre of Surgery | Recruiting | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT07318584 Comparator | Mar 2026 → Feb 2028 expected | escherichia coli discitis | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06048692 Comparator | Jan → Sep 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT01888822 Comparator | Jun 2013 → Jun 2016 | cholelithiasis | University of Roma La Sapienza | Terminated | No outcome recorded |
| Phase 4 | NCT00630513 Comparator | Jan 2008 → Jun 2010 | infectious peritonitis | University of Bologna | Completed | No outcome recorded |
| Phase 4 | NCT00368537 Comparator | Sep 2006 → Sep 2008 | skin disease caused by bacterial infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| — | NCT07118384 Comparator | May 2025 → Jan 2026 overdue | Acinetobacter infectious disease | Cairo University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ampicillin/Sulbactam | “Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗14“To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii...” NCT07118384 ↗ “Pregnant women (n=100) received IV Ampicillin/Sulbactam (AMS) (Unictam® 1500 mg) 30 minutes before CD and 12 hours after CD” NCT06048692 ↗ “Ampicillin/sulbactam versus cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study.” PMID 21118502 ↗ Nov 2010 “Ampicillin-Sulbactam*” NCT02099240 ↗ |
| Known as | AMS | “Pregnant women (n=100) received IV Ampicillin/Sulbactam (AMS) (Unictam® 1500 mg) 30 minutes before CD and 12 hours after CD” NCT06048692 ↗ |
| Action | Inhibit | “Sulbactam, a beta-lactamase inhibitor, is commercially available mainly in combination with β-lactam antibiotics” NCT07118384 ↗ |
| Route | Intravenous | “Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs” NCT00368537 ↗ |